TGRX-678
Phase 3Small molecule
TGRX-678 is one of 18 small molecule programs targeting Chronic Myelogenous Leukemia. It is currently in Phase 3.
1
Indications
6
Total Trials
4
Active Trials
17
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Chronic Myelogenous Leukemia
#DrugCompanyPhaseTrials
1Gleevec
NovartisApproved
Tasigna
AAzurity Pharmaceuticals
Approved
Sprycel
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Bosulif
PPrism Pharmaceuticals
Approved
Tukysa
PfizerApproved
Depakote
AbbVieApproved
Jakafi
IncyteApproved
Scemblix
NovartisPhase 3
Nizoral
WWim Janssens
Approved
Nerlynx
PPuma Biotechnology, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic Myelogenous Leukemia4 trials
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TGRX-678. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- SShenzhen TargetRx Co., Ltd.